The Preventative COVID-19 Study at Velocity Clinical Research in New Smyrna Beach

The Team

Although we are constantly striving to learn more, we don’t yet know nearly enough about COVID-19. We consistently make good headway in our war waged against this virus, but we have a long way to go to ensure the safety of the people in our country and our world through effective preventative measures and treatments for the COVID-19 virus.

That’s where Velocity New Smyrna Beach comes into play. Velocity Clinical Research, formerly Riverside Clinical Research, is one of the most innovative and trusted clinical research facilities in existence today and conducts a broad range of clinical studies with the goal of discovering an even wider array of remarkable treatments.

This team of highly skilled medical professionals is dedicated to the development of innovative disease preventions and treatments and to treating each and every patient with the utmost compassion, kindness and care as we strive to attain those goals. 

Velocity Clinical Research is also proud to remain steadfast in its commitment with its unsurpassed longevity in operational excellence and the highest quality clinical results. Founded in 2017, the focus of Velocity Clinical Research has been centered on clinical trials for over 250 years and includes over 5,000 successfully completed clinical studies. 

At Velocity Clinical Research, we are all honored to work among such an accomplished group of research professionals…medical professionals who consistently exhibit extraordinary passion in their pursuit of medical progress, with the ultimate goal of improved care and quality of life; an unwavering moral compass; and an enviable work-ethic, which consistently yields an impressive level of productivity as well as consummate patient care.

Study volunteers provide an enormous contribution to everything that is possible through the advanced research at Velocity Clinical Research. These clinical trial volunteers play an integral part in ensuring that our world is filled with hope and possibility. 

The Study

Velocity New Smyrna Beach is currently enrolling individuals with underlying conditions in a COVID-19 study to evaluate the efficacy and safety of a monoclonal antibody in the prevention of COVID-19. To qualify, study participants must have no history of a positive COVID-19 infection and have not received a COVID vaccine. 

If a potential study participant is unsure of whether or not they have had COVID, the research team at Velocity New Smyrna Beach is able to perform a test at screening which will determine if they possess antibodies to the COVID-19 virus. If the clinical study volunteer is in possession of these COVID-19 antibodies, they will be disqualified from participation in the study, but will receive a screening payment of $125 to cover their time.

This Velocity Research phase three clinical trial is part of a study in which the sponsor is developing the antibody as a preventative treatment for COVID-19. The study, the Andagio antibody study, will test an investigational drug called ADG20, which is not yet approved by any governing regulatory bodies including the Food & Drug Administration (FDA). The antibody under scrutiny works by targeting a part of the virus called the spike protein, which activates the virus. It doesn’t force the body to produce viral particles or spike protein. It works more like a shield, providing protection while it is in the body, but not altering anatomy or physiology in any way. It is expected that the antibody will last approximately one year before disappearing from the body. The clinical trial is 14 months in length and will provide a compensation of $125 for each visit.

The study will investigate the safety of the antibody by monitoring each participant for side effects, changes in vital signs and through laboratory blood test results. The efficacy of the antibody will be determined by benefits including:

  • Whether or not the antibody lowers a study participant’s chances of becoming infected with SARS- CoV-2 and subsequently developing COVID-19; 
  • Whether or not the presence of the antibody within the body reduces the severity of COVID-19 symptoms if a study participant happens to contract the COVID-19 virus; 
  • And whether or not the antibody in question prevents a clinical study participant from developing COVID-19 if it is administered shortly after the participant has been exposed to an individual with COVID-19.

Why Participate?

Along with joining the noble fight against COVID-19, clinical trial participants may benefit from access to innovative treatments well before they become available to the general public through commercial markets. Velocity Clinical Research volunteers are also compensated for their time, there are no costs associated with the medical procedures or treatments provided in this clinical study and there is no insurance necessary to participate.

How to Participate

If you are interested in participating in the Velocity research study aimed at evaluating the efficacy and safety of a monoclonal antibody for the purpose of preventing COVID-19, simply contact the professionals at Velocity Clinical Research to learn more. You can reach us at 386-428-7730 Monday through Thursday from 7 a.m. to 5 p.m. or Friday from 7 a.m. to 12 p.m. You are also welcome to access the patient portal on our website and enroll with Velocity Clinical Research so that you may be contacted about studies conducted in your area. Velocity Clinical Research can also be reached by email at info@velocityclinicalresearch.com

The Velocity Clinical Research experienced physicians, research personnel and clinical trial coordinators work closely with clinical trial volunteers to deliver exceptional patient care and closely monitor and assess the benefits and effectiveness of preventative measures and treatments. World-renowned and capable of supporting up to 26 in-house patients and a large number of outpatients, Velocity Clinical Research is conveniently located nearby the historic seaside town of New Smyrna and of the charm and beauty it has to offer.